StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3035% above fair value
$8.64−0.27 (-3.03%)

Close on Nov 20, 2026Market cap $737.11MP/E –Yield –

Monte Rosa Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Monte Rosa Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$32.08M, down 234.5% year over year. For fiscal 2025 it was -$27.50M, down 172.3% from the year before. The highest annual figure on record is $38.01M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.50M-172.3%
FY2024Dec 31, 2024$38.01M–
FY2023Dec 31, 2023-$62.84M–
FY2022Dec 31, 2022-$105.38M–
FY2021Dec 31, 2021-$69.10M–
FY2020Dec 31, 2020-$26.44M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.84M–
Q1 FY2026Mar 31, 2026-$39.24M–
Q4 FY2025Dec 31, 2025-$43.78M-134.0%
Q3 FY2025Sep 30, 2025$99.78M–
Q2 FY2025Jun 30, 2025-$36.42M–
Q1 FY2025Mar 31, 2025-$47.08M–
Q4 FY2024Dec 31, 2024$128.74M+360.7%
Q3 FY2024Sep 30, 2024-$21.39M–
Q2 FY2024Jun 30, 2024-$29.79M–
Q1 FY2024Mar 31, 2024-$39.55M–
Q4 FY2023Dec 31, 2023$27.95M–
Q3 FY2023Sep 30, 2023-$26.37M–
Q2 FY2023Jun 30, 2023-$31.84M–
Q1 FY2023Mar 31, 2023-$32.59M–
Q4 FY2022Dec 31, 2022-$31.23M–
Q3 FY2022Sep 30, 2022-$22.00M–
Q2 FY2022Jun 30, 2022-$23.05M–
Q1 FY2022Mar 31, 2022-$29.09M–
Q4 FY2021Dec 31, 2021-$17.23M–
Q3 FY2021Sep 30, 2021-$19.55M–
Q2 FY2021Jun 30, 2021-$16.28M–
Q1 FY2021Mar 31, 2021-$16.03M–
Q4 FY2020Dec 31, 2020-$9.76M–
Q3 FY2020Sep 30, 2020-$7.82M–

More Monte Rosa Therapeutics figures

See a number that looks wrong?